Alexander Schneider
Founder and CEO of CureLab and developer of Elanogen, a plasmid-based therapy targeting P62 to modulate immune presentation and chronic inflammation in cancer and other diseases.
Best podcasts with Alexander Schneider
Ranked by the Snipd community
Feb 17, 2026 • 45min
A Plasmid-Based Cancer Therapy - Dr. Alexander Schneider
Dr. Alexander Schneider, founder and CEO of CureLab and developer of Elanogen, a plasmid therapy targeting P62. He discusses plasmid delivery and why P62 makes cancer cells vulnerable. Short takes on how some chemotherapies work through immune effects, how drugs like gemcitabine can trigger chronic inflammation, and promising clinical signals combining Elanogen with standard treatments.
